|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Shire_plc
|
|
gptkbp:acquisitionYear
|
2019
|
|
gptkbp:CEO
|
gptkb:Christophe_Weber
|
|
gptkbp:chairman
|
gptkb:Masami_Iijima
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:foundedBy
|
gptkb:Chobei_Takeda_I
|
|
gptkbp:foundedYear
|
1781
|
|
gptkbp:globalPresence
|
over 80 countries
|
|
gptkbp:hasResearchCenter
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:headquartersLocation
|
gptkb:Nihonbashi,_Chuo-ku,_Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Takeda Pharmaceuticals
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:Nikkei_225
gptkb:TOPIX_Core30
|
|
gptkbp:memberOf
|
gptkb:Japan_Pharmaceutical_Manufacturers_Association
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
-142.8 billion yen (FY2023)
|
|
gptkbp:notableProduct
|
gptkb:Alunbrig
gptkb:Adcetris
gptkb:Aloxi
gptkb:Entyvio
gptkb:Gammagard
gptkb:Natpara
gptkb:Ninlaro
gptkb:Takhzyro
gptkb:Velcade
gptkb:Vyvanse
|
|
gptkbp:numberOfEmployees
|
~49,000
|
|
gptkbp:products
|
oncology drugs
prescription drugs
vaccines
plasma-derived therapies
gastroenterology drugs
rare diseases drugs
|
|
gptkbp:revenue
|
3.569 trillion yen (FY2023)
|
|
gptkbp:slogan
|
Better Health, Brighter Future
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4502
|
|
gptkbp:subsidiary
|
gptkb:ARIAD_Pharmaceuticals
gptkb:Millennium_Pharmaceuticals
gptkb:Nycomed
gptkb:Shire_plc
gptkb:Takeda_Oncology
|
|
gptkbp:therapeuticArea
|
neuroscience
oncology
vaccines
gastroenterology
rare diseases
plasma-derived therapies
|
|
gptkbp:website
|
https://www.takeda.com/
|
|
gptkbp:bfsParent
|
gptkb:Tadataka_Yamada
|
|
gptkbp:bfsLayer
|
6
|